Jafron Biomedical Co.,Ltd. (SHE:300529)
China flag China · Delayed Price · Currency is CNY
19.79
-0.25 (-1.25%)
At close: Feb 13, 2026

Jafron Biomedical Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
15,32522,72017,75524,74142,65354,196
Market Cap Growth
-33.25%27.96%-28.23%-41.99%-21.30%80.19%
Enterprise Value
14,26921,62716,80323,82241,39452,930
Last Close Price
19.7928.2921.1328.7548.5261.31
PE Ratio
31.4427.7040.6827.8135.6461.92
Forward PE
27.9720.9120.4614.2031.2853.74
PS Ratio
7.528.499.249.9315.9427.78
PB Ratio
4.476.815.636.8912.6119.13
P/TBV Ratio
4.617.045.857.2013.2720.28
P/FCF Ratio
26.4827.8526.5260.6559.9190.27
P/OCF Ratio
20.3621.6219.3727.9934.1456.60
EV/Sales Ratio
7.008.088.749.5615.4727.13
EV/EBITDA Ratio
19.2819.3229.3023.9230.1552.81
EV/EBIT Ratio
24.1221.6734.7925.7131.2754.82
EV/FCF Ratio
24.6626.5125.1058.4058.1488.16
Debt / Equity Ratio
0.420.420.530.360.27-
Debt / EBITDA Ratio
1.931.232.901.280.67-
Debt / FCF Ratio
2.471.702.503.131.29-
Net Debt / Equity Ratio
-0.31-0.28-0.36-0.36-0.46-0.56
Net Debt / EBITDA Ratio
-1.43-0.83-1.98-1.29-1.13-1.57
Net Debt / FCF Ratio
-1.82-1.14-1.70-3.14-2.18-2.62
Asset Turnover
0.370.490.350.490.670.68
Inventory Turnover
1.371.441.071.612.542.70
Quick Ratio
3.693.103.493.917.215.44
Current Ratio
4.263.633.994.597.916.01
Return on Equity (ROE)
14.20%25.10%12.63%25.26%38.47%34.89%
Return on Assets (ROA)
6.64%11.42%5.51%11.33%20.61%21.13%
Return on Invested Capital (ROIC)
19.85%36.51%18.25%38.79%56.14%75.72%
Return on Capital Employed (ROCE)
12.20%21.60%10.20%19.70%29.90%33.50%
Earnings Yield
3.14%3.61%2.46%3.60%2.81%1.62%
FCF Yield
3.78%3.59%3.77%1.65%1.67%1.11%
Dividend Yield
4.04%2.83%1.89%2.33%1.85%1.08%
Payout Ratio
134.11%41.47%128.71%82.00%44.37%43.17%
Buyback Yield / Dilution
3.68%1.57%0.08%1.12%0.89%-2.22%
Total Shareholder Return
7.62%4.40%1.97%3.45%2.74%-1.14%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.